BGB-900-102

Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumour Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination with Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients with Advanced Solid Tumours

Enquire

Trial overview

Clinical Area

Medical Oncology

Disease / Condition

Solid tumours

Study Phase

I-II

Trial registration

Number: NCT03744468

https://clinicaltrials.gov/study/NCT03744468

GenesisCare Location(s)

Calvary North, Adelaide

Principal Investigator(s)

Vy Broadbridge

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.

First name *

Last name *

Email *

Phone *

State *

Postcode *

What is the reason for enquiry?

How would you prefer to be contacted? *

Phone

By submitting you acknowledge we will use the information you are providing to contact you about your enquiry. For more information about how we handle your personal information, please refer to the GenesisCare Privacy Policy.

BGB-900-102

Trial overview

Thank you for submitting.

An unexpected error has occurred.

How can we help?

GenesisCare

Website policies

Contact us

Connect with us